Market Overview

Cytokinetics Earnings Outlook

Related CYTK
The Daily Biotech Pulse: Genomic Health Earnings, AbbVie's Humira Approved For Another Indication In Japan
Jim Cramer Gives His Opinion On Netflix, Kraft Heinz And More
Cytokinetics Inc. (CYTK) CEO Robert Blum on Q4 2018 Results - Earnings Call Transcript (Seeking Alpha)

Cytokinetics (NASDAQ: CYTK) announces its next round of earnings Thursday. Here is Benzinga's everything-that-matters guide for today's Q4 earnings announcement.

Earnings and Revenue

Sell-side analysts are expecting Cytokinetics's loss per share to be near 70 cents on sales of $6.32 million.

In the same quarter last year, Cytokinetics reported earnings per share of 16 cents per share on revenue of $33.1 million. If the company were to match the consensus estimate when it reports Thursday, EPS would have fallen 537.5 percent. Sales would be down 80.93 percent on a year-over-year basis.

Here's how the Cytokinetics's reported EPS has stacked up against analyst estimates in the past:


Quarter Q3 2017 Q2 2017 Q1 2017 Q4 2016
EPS Estimate -0.61 -0.59 -0.27 -0.4
EPS Actual -0.6 -0.6 -0.62 0.16


Stock Performance

Over the last 52-week period, shares are down 23.13 percent. Given that these returns are generally negative, long-term shareholders are probably a little upset going into this earnings release.

Analyst estimates are adjusted lower for EPS and revenues over the past 90 days. The popular rating by analysts on Cytokinetics stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.

Conference Call

Cytokinetics' Q4 conference call is scheduled to begin at 4:00 p.m. ET and can be accessed here:

Posted-In: Earnings News Previews Trading Ideas


Related Articles (CYTK)

View Comments and Join the Discussion!

Every Executive Who's Disappeared From Snap Since Its IPO

Shake Shack Q4 Earnings Preview